Persistent Yeast Infection Treatment: Medical & Lifestyle Strategies

Recurrent vulvovaginal candidiasis (RVVC) = ≥4 culture-proven episodes/year. Requires confirmed diagnosis and tailored management.

Diagnostic Confirmation

• KOH prep (pseudohyphae/budding yeasts) or fungal culture (species ID: C. albicans 85–90%, C. glabrata, C. tropicalis – azole-resistant).
• Rule out: BV, trichomonas, dermatoses (lichen sclerosus, contact dermatitis), HSV, cytolytic vaginosis.

Therapeutic Ladder

1. Induction (Acute Episode):
   • C. albicans: Fluconazole 150 mg PO Day 1, 4, 7 (3-dose) OR topical azole ×7–14 days.
   • Non-albicans: Boric acid 600 mg vaginal suppository nightly ×14 days (first-line for azole-resistant); Flucytosine 15% cream ± amphotericin B.
2. Maintenance Suppression (RVVC):
   • Fluconazole 150 mg PO weekly ×6 months (reduce to monthly if remission).
   • Alternative: Itraconazole 200 mg daily ×6 mo; boric acid 600 mg 2×/week.
3. Adjunctive:
   • Probiotics: L. rhamnosus GR-1 + L. reuteri RC-14 (oral/vaginal) – modest recurrence reduction.
   • Diet: Low refined sugar; limited evidence.
   • Glycemic control if diabetic.
   • Avoid irritants: douches, scented products, tight synthetics.

Partner Treatment

Not routinely recommended (sexual transmission minor); treat if symptomatic (balanitis).

When to Refer

• Failure of maintenance suppression.
• Non-albicans species unresponsive to boric acid.
• Immunocompromised host.
• Suspected dermatosis (biopsy).

RVVC is manageable; species-directed therapy + maintenance prevents most recurrences.